ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in nmCRPC and Final Results from the ACIS Phase 3 Study – Discussion
(UroToday.com) Following presentations by Dr. Felix Feng assessing molecular determinants of response to apalutamide in patients with non-metastatic prostate cancer and by Dr. Dana Rathkopf looking at the ACIS trial combining apalutamide and abiraterone acetate in patients with newly diagnosed metastatic castration-resistant prostate cancer, Dr. Joshi Alumkal provided a discussion of these data in the Oral […]